Artivion (AORT) Q4 2025: Stent Graft Revenue Jumps 36%, Propelling Double-Digit Growth Outlook
Stent graft and Onyx product lines drove robust Q4 momentum, with operational leverage visible in margin expansion. Artivion’s 2025 execution highlights the power of differentiated clinical data and pipeline innovation, while 2026 guidance signals confidence in sustained double-digit growth. Investors should watch for U.S. adoption curves and new PMA catalysts as core franchises scale.
Summary
- Stent Graft Expansion Accelerates: Portfolio strength and new clinical data fuel U.S. and international growth.
- Margin Leverage Materializes: EBITDA margin expansion driven by SG&A efficiency and product mix.
- Pipeline Catalysts Ahead: PMA approvals and new account penetration set up multi-year growth runway.
Business Overview
Artivion is a global medical device company specializing in aortic disease treatment products, including stent grafts, mechanical heart valves, tissue processing, and surgical adhesives. The company generates revenue through sales of proprietary devices and preservation services to hospitals and surgeons worldwide. Its four primary segments are stent grafts, Onyx mechanical valves, tissue processing, and BioGlue surgical adhesive, with a growing focus on the U.S. market and expansion into Europe and Asia-Pacific.
Performance Analysis
Artivion delivered a standout Q4, with adjusted constant currency revenue growth of 18.5% and EBITDA up 29% year-over-year, underpinned by strong execution in stent grafts (+36%) and Onyx valves (+24%). The quarter benefited from easier comps due to last year’s cyber incident, but even after normalizing for this, underlying business growth remained robust at 13%. Segment strength was broad-based, with Asia-Pacific leading regional gains (+32%), followed by North America (+18%) and EMEA (+17%).
Margin expansion was a highlight, with EBITDA margin rising 110 basis points to 19.2%, reflecting significant SG&A leverage and operational discipline. Gross margins held steady at 63% despite one-time headwinds from the Italian payback adjustment and lingering manufacturing inefficiencies, which management does not expect to repeat. Free cash flow exceeded expectations, aided by disciplined investment and insurance recoveries related to the prior cyber event.
- Stent Graft Portfolio Drives Growth: U.S. AMDS launch and international traction are foundational to revenue acceleration.
- Onyx Adoption Gains Momentum: New clinical data and cardiologist education are expanding the addressable market for younger patients.
- Expense Control Yields Margin Gains: SG&A efficiency and stable R&D investment support sustainable profitability improvements.
Despite a soft tissue processing recovery post-cyber incident, the company’s product mix and operational execution position it for continued margin and cash flow gains as new products scale.
Executive Commentary
"2025 was a highly successful year for Artivion, during which our team made meaningful progress against our strategy design to drive long-term growth, profitable growth through our expanding and clinically differentiated product portfolio."
Pat Matkin, Chief Executive Officer
"Adjusted EBITDA grew 26% for the full year, twice the rate of adjusted revenue growth. This resulted in an adjusted EBITDA margin of 20.2%, a 190 basis point improvement from 2024."
Lance Berry, Chief Operating Officer and Chief Financial Officer
Strategic Positioning
1. Stent Graft Leadership and U.S. Penetration
Stent grafts, minimally invasive vascular implants, anchor Artivion’s growth strategy. The U.S. AMDS launch is still in its early innings, with only 10% of target accounts opened in 2025, suggesting substantial runway as new accounts come online and utilization deepens. Management’s analogy to being in the “first inning” underscores the opportunity for further penetration and sustained growth as FDA approval and reimbursement tailwinds accelerate adoption.
2. Onyx Valve Market Expansion
Onyx, a mechanical heart valve with low INR requirements, is capturing share in the under-65 patient segment, supported by new clinical evidence and targeted cardiologist education. The company is investing in formal marketing and physician outreach, aiming to convert positive market research into higher referral rates and branded demand, which could drive upside to mid-teens growth guidance.
3. Pipeline and Regulatory Catalysts
Multiple PMA (pre-market approval) milestones are on the horizon, including AMDS (mid-2026), Nexus (second half 2026), and Artisan (2029). Each unlocks incremental addressable market, with Nexus positioned as a “platform technology” for high-risk aortic arch patients, and Artisan targeting a new $80 million U.S. market.
4. Operational Discipline and Margin Expansion
SG&A leverage and disciplined R&D investment are driving sustained EBITDA margin expansion, with further improvements expected as product mix shifts toward higher-margin U.S. stent grafts and Onyx valves. CapEx is temporarily elevated to support Onyx manufacturing scale-up and IT systems, but management expects normalization post-2026.
5. Cross-Selling and Account Synergy
Cross-selling between AMDS and Onyx is emerging as a force multiplier, as new AMDS accounts open doors for Onyx adoption among surgeons previously outside the company’s network. Management expects this dynamic to continue for several years, supporting both penetration and share gains.
Key Considerations
Artivion’s Q4 and full-year results reflect a business executing on differentiated clinical value, disciplined investment, and a multi-year pipeline strategy. Strategic context for the quarter centers on:
Key Considerations:
- U.S. Launch Trajectory: AMDS and Onyx adoption curves remain in the early stages, with significant account opening and physician education still ahead.
- Pipeline Approval Timing: PMA milestones for AMDS and Nexus are critical to unlocking new revenue streams and maintaining double-digit growth.
- Margin Sustainability: SG&A leverage and manufacturing efficiency gains are supporting margin expansion, but ongoing R&D investment will be needed to sustain innovation.
- Tissue Processing Recovery: This legacy segment remains flat, limiting upside, but is no longer a major drag on overall growth.
Risks
Key risks include execution on U.S. launches, particularly the pace of AMDS and Onyx account penetration and physician adoption. Regulatory delays or setbacks in PMA approvals could push out revenue inflection points. Margin expansion is partly contingent on mix shift and operational discipline, while elevated CapEx and R&D investment could pressure free cash flow if growth expectations are not met. Macro reimbursement changes or competitive entries in core product categories also warrant monitoring.
Forward Outlook
For Q1 2026, Artivion expects:
- Constant currency revenue growth at the high end of the 10% to 14% full-year range.
- Lower growth rates in subsequent quarters as comps normalize.
For full-year 2026, management guided:
- Reported revenue of $486 to $504 million (10% to 14% growth).
- Adjusted EBITDA of $105 to $110 million, 18% to 22% growth and 150 basis points margin expansion.
- Gross margin improvement of 50 basis points, driven by favorable product mix.
- CapEx of approximately $50 million, primarily for Onyx capacity and IT systems.
Management cited confidence in “sustainable double-digit revenue growth” and EBITDA growth at roughly twice the revenue rate over the long term, with PMA timing and account ramp pacing as key swing factors.
- Stent graft and Onyx adoption rates will be the primary determinants of upside or downside to guidance.
- Pipeline milestones could accelerate market expansion if approvals are secured on schedule.
Takeaways
Artivion’s Q4 showcased the power of differentiated technology and disciplined execution, with stent grafts and Onyx leading the way. As new account penetration and regulatory milestones approach, the company is positioned for sustained growth, but execution risk around U.S. launches and pipeline approvals remains material.
- Growth Engine: Stent graft and Onyx franchises are scaling, with early innings of U.S. adoption and significant market opportunity still ahead.
- Margin Story: Operational leverage and SG&A discipline are driving EBITDA margin gains, with potential for further improvement as mix shifts to higher-value products.
- Pipeline Watch: PMA approvals for AMDS and Nexus in 2026 are the next major catalysts; investors should track progress on trial enrollment and regulatory submissions.
Conclusion
Artivion’s 2025 performance validates its growth strategy, with strong execution in core product lines and a clear pipeline for future expansion. Sustained double-digit growth and margin gains are within reach, but investors should monitor U.S. adoption pacing and regulatory progress as the next phase unfolds.
Industry Read-Through
Artivion’s results reinforce the value of differentiated clinical data and targeted physician education in driving adoption of advanced cardiovascular devices. The success of the AMDS and Onyx launches highlights the importance of early account penetration and cross-selling in specialty medtech. The Italian payback adjustment is a reminder of the regulatory complexity facing global device makers, while the operational leverage achieved demonstrates that scale and mix shift can materially improve profitability even in R&D-intensive sectors. Competitors in aortic and structural heart markets should note the multi-year runway created by PMA catalysts and the need for robust post-market evidence to capture share in evolving indications.